New Data Bolsters Cosentyx In AS & PsA; Humira Head-To-Head Planned
Executive Summary
Novartis AG has unveiled fresh data supporting the efficacy of its Cosentyx (secukinumab) drug in ankylosing spondylitis and psoriatic arthritis along with plans to compare that front-running anti-IL-17A agent against AbbVie Inc.'s anti-TNF competitor Humira (adalimumab) in head-to-head clinical trials.
You may also be interested in...
Novartis' Cosentyx Boosted By High Psoriasis Skin Clearance Over 4 Years
Data showing Novartis' Cosentyx maintained high levels of skin clearance in psoriasis patients along with a favorable safety profile after four years should give the drug an advantage over new interleukin inhibitors undergoing Phase III trials in psoriasis.
Indication-Based Pricing Could Be Windfall For Interleukin Inhibitors
Express Scripts' plan to reimburse at levels according to value of specific indications in inflammatory diseases will create more space for new entrants with proven value.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.